1. Acknowledgement

   Acknowledgments 12 December 2012 Pages: 359 - 360

2. Insensitivity to Scope in Contingent Valuation Studies

   • Jennifer A. Whitty

   Editorial 12 December 2012 Pages: 361 - 363

3. Inclusion of Compliance and Persistence in Economic Models

   • Ananth Kadambi
   • Robert J. Leipold
   • Denis Getsios

   Review Article 12 December 2012 Pages: 365 - 379

4. Cost Effectiveness of Guanfacine Extended-Release versus Atomoxetine for the Treatment of Attention-Deficit/Hyperactivity Disorder

   • M. Haim Erder
   • Jipan Xie
   • Vanja Sikirica

   Original Research Article 12 December 2012 Pages: 381 - 395

   

5. Insensitivity to Scope in Contingent Valuation Studies

   • Rikke Søgaard
   • Jes Lindholt
   • Dorte Gyrd-Hansen

   Original Research Article 12 December 2012 Pages: 397 - 405

   

6. What Explains Willingness to Pay for Smoking-Cessation Treatments —Addiction Level, Quit-Rate Effectiveness or the Opening Bid?

   • Jan Abel Olsen
   • Ole J. Røgeberg
   • Knut Stavem

   Original Research Article 12 December 2012 Pages: 407 - 415

   

7. Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain

   • Tatiana Dilla
   • Amparo Valladares
   • María Costi

   Original Research Article Open access 12 December 2012 Pages: 417 - 430

   

8. Economic Implications of Rasburicase Treatment in Adult Patients with Tumour Lysis Syndrome

   • Michael Eaddy
   • Brian Seal
   • Ken O’Day

   Original Research Article 12 December 2012 Pages: 431 - 440

   

9. Do Higher-Priced Generic Medicines Enjoy a Competitive Advantage Under Reference Pricing?

   • Jaume Puig-Junoy

   Original Research Article 12 December 2012 Pages: 441 - 451